Trevi Therapeutics, Inc. (TRVI) shareholders
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Scott D. Sandell Joint filing with New Enterprise Associates 16, L.P. (12.00%), NEA Partners 16, L.P. (12.00%) and 10 more | 15,074,080 | 12.00% | 13D (active) amendment | Aug 7, 2025 |
| Ali Behbahani Joint filing with New Enterprise Associates 16, L.P. (15.00%), NEA Partners 16, L.P. (15.00%) and 10 more | 15,074,080 | 15.00% | 13D (active) amendment | Mar 18, 2025 |
| Nea 18 Vge Gp, LLC Joint filing with Paul Walker (11.60%), NEA Partners 16, L.P. (11.60%) and 10 more | 15,074,080 | 11.60% | 13D (active) amendment | Aug 7, 2025 |
| Paul Walker Joint filing with New Enterprise Associates 16, L.P. (10.50%), NEA Partners 16, L.P. (10.50%) and 10 more | 15,074,080 | 10.50% | 13D (active) amendment | May 5, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (8.80%) | 12,562,839 | 8.80% | 13G (passive) amendment | Jun 30, 2026 |
| Patrick J. Heron Joint filing with James N. Topper (10.60%), Frazier Life Sciences Public Fund, L.P. (8.80%) and 4 more | 10,259,409 | 10.60% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 9,779,593 | 6.90% | 13G (passive) amendment | Sep 30, 2026 |
| Fhmlsp, L.P. Joint filing with Frazier Life Sciences Public Fund, L.P. (7.00%), Fhmlsp, L.L.C. (7.00%) | 8,508,021 | 7.00% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (6.30%) | 8,038,061 | 6.30% | 13G (passive) amendment | Mar 31, 2026 |
| Ott David C. Joint filing with Viking Global Investors LP (5.90%), Viking Global Opportunities Parent GP LLC (5.90%) and 2 more | 7,505,694 | 5.90% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TRVI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 13,222,228 | 9.28% | $246.59M | – | 15.53% |
| FMR LLC | 12,562,839 | 8.82% | $234.30M | +4,524,778 | 0.01% |
| BlackRock, Inc. | 11,155,026 | 7.83% | $208.04M | +914,840 | 0.00% |
| Frazier Life Sciences Management, L.P. | 9,939,447 | 6.98% | $185.37M | −100 | 4.04% |
| Wellington Management Group Llp | 5,684,592 | 3.99% | $106.02M | +495,504 | 0.02% |
| Vanguard Capital Management LLC | 5,530,675 | 3.88% | $103.15M | +552,108 | 0.00% |
| Vivo Capital, LLC | 5,094,668 | 3.58% | $95.02M | – | 8.68% |
| Woodline Partners LP | 4,081,333 | 2.86% | $76.12M | +3,080,551 | 0.24% |
| Vestal Point Capital, LP | 3,100,000 | 2.18% | $57.82M | +933,496 | 1.35% |
| Mpm Bioimpact LLC | 3,073,577 | 2.16% | $57.32M | −224,853 | 3.50% |
| Frontier Capital Management Co LLC | 3,070,740 | 2.16% | $57.27M | +1,076,448 | 0.53% |
| Assenagon Asset Management S.A. | 3,050,628 | 2.14% | $56.89M | New | 0.04% |
| State Street Corp | 3,027,315 | 2.12% | $56.46M | +362,002 | 0.00% |
| Geode Capital Management, LLC | 2,928,068 | 2.06% | $54.62M | +149,837 | 0.00% |
| Marshall Wace, Llp | 2,674,137 | 1.88% | $49.87M | −1,291,882 | 0.04% |
| Eventide Asset Management, LLC | 2,660,000 | 1.87% | $49.61M | +37,694 | 0.66% |
| Rubric Capital Management LP | 2,504,513 | 1.76% | $46.71M | −1,207,860 | 0.43% |
| Alliancebernstein L.P. | 2,355,453 | 1.65% | $28.10M | −490,019 | 0.01% |
| Artia Global Partners LP | 2,210,852 | 1.55% | $41.23M | +197,250 | 7.61% |
| Acorn Capital Advisors, LLC | 2,144,844 | 1.51% | $40.00M | – | 10.92% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 218 | 151M | 100.0% | 43 / 89 | 60 / 20 | 28M | 13M |
| Q1 2026 | 198 | 135M | 94.7% | 41 / 65 | 62 / 25 | 22M | 10M |
| Q4 2025 | 184 | 130M | 91.5% | 34 / 74 | 49 / 14 | 19M | 18M |
| Q3 2025 | 164 | 129M | 90.8% | 35 / 65 | 42 / 23 | 30M | 17M |
| Q2 2025 | 153 | 115M | 81.1% | 39 / 64 | 32 / 23 | 40M | 13M |
| Q1 2025 | 137 | 88M | 61.9% | 42 / 54 | 31 / 14 | 23M | 14M |
| Q4 2024 | 110 | 79M | 55.8% | 26 / 47 | 24 / 7 | 27M | 6M |
| Q3 2024 | 93 | 58M | 40.9% | 19 / 31 | 19 / 2 | 8M | 5M |
| Q2 2024 | 77 | 59M | 41.2% | 6 / 36 | 16 / 9 | 8M | 1M |
| Q1 2024 | 80 | 52M | 36.3% | 22 / 16 | 27 / 5 | 5M | 6M |
| Q4 2023 | 63 | 52M | 36.8% | 12 / 27 | 13 / 4 | 9M | 6M |
| Q3 2023 | 55 | 49M | 34.2% | 6 / 13 | 17 / 4 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
171 funds held TRVI in Q2 2026, 36% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TRVI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,047,125 | 2.84% | $75.48M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,750,819 | 1.93% | $51.30M | 0.06% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 2,660,000 | 1.87% | $49.61M | 2.77% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 2,374,785 | 1.67% | $33.58M | 0.64% | May 31, 2026 |
| Fidelity Small Cap Growth Fund | 1,950,341 | 1.37% | $35.59M | 0.40% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,353,312 | 0.95% | $25.24M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,172,697 | 0.82% | $21.40M | 0.06% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 1,040,299 | 0.73% | $14.71M | 0.01% | May 31, 2026 |
| AB Small Cap Growth Portfolio | 1,034,886 | 0.73% | $19.30M | 0.62% | Jun 30, 2026 |
| Select Health Care Portfolio | 1,000,000 | 0.70% | $14.14M | 0.24% | May 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 990,061 | 0.69% | $18.07M | 0.39% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 989,279 | 0.69% | $18.45M | 0.12% | Jun 30, 2026 |
| SmallCap Growth Fund I | 776,604 | 0.55% | $14.17M | 0.57% | Jul 31, 2026 |
| VIP Mid Cap Portfolio | 764,700 | 0.54% | $14.26M | 0.15% | Jun 30, 2026 |
| iShares Biotechnology ETF | 658,159 | 0.46% | $12.27M | 0.14% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jennifer L. Good | President & CEO, Director | 213,313 | 0.15% | Feb 20, 2026 |
| Farrell Simon | Chief Commercial Officer | 81,250 | 0.06% | Feb 20, 2026 |
| Christopher Galletta | See Remarks | 26,095 | 0.02% | Feb 20, 2026 |
| Thomas Sciascia | Chief Scientific Officer | 224,004 | 0.16% | Feb 20, 2026 |
| James V. Cassella | Chief Development Officer | – | – | Feb 20, 2026 |
| David C. Hastings | Chief Financial Officer | – | – | Jan 12, 2026 |
| Lisa Delfini | Chief Financial Officer | 64,660 | 0.05% | Jun 3, 2025 |
| Michael Thomas Heffernan | Director | 6,351 | 0.00% | Sep 17, 2026 |
| Anne Vanlent | Director | 20,983 | 0.01% | Jun 4, 2026 |
| Dominick Colangelo | Director | – | – | Jun 4, 2026 |
| Edward T. Mathers | Director | 948,948 | 0.67% | Jun 4, 2026 |
| David P. Meeker | Director | 1,021,696 | 0.72% | Jun 4, 2026 |
| Carmen Chang | 10% owner | 13,222,228 | 9.28% | Feb 13, 2026 |
| Paul Edward Walker | 10% owner | 13,222,228 | 9.28% | Feb 13, 2026 |
| Scott D. Sandell | 10% owner | 13,222,228 | 9.28% | Feb 13, 2026 |
| Mohamad Makhzoumi | 10% owner | 13,222,228 | 9.28% | Feb 13, 2026 |
| Anthony A. Florence Jr. | 10% owner | 13,222,228 | 9.28% | Feb 13, 2026 |
| Ali Behbahani | 10% owner | 13,222,228 | 9.28% | Feb 13, 2026 |
| Forest Baskett | 10% owner | 12,273,280 | 8.61% | Feb 13, 2026 |
| New Enterprise Associates 16, L.P. | 10% owner | 5,938,562 | 4.17% | Feb 13, 2026 |
| NEA Partners 16, L.P. | 10% owner | 12,273,280 | 8.61% | Feb 13, 2026 |
| Nea 16 Gp, Llc | 10% owner | 10,421,428 | 7.31% | Feb 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Thomas Heffernan Director | Sep 15, 2026 | Sale(10b5-1 plan) | −100 | $15.88 | $1.59K | 6,351 |
| Michael Thomas Heffernan Director | Sep 15, 2026 | Sale(10b5-1 plan) | −20,952 | $15.09 | $316.17K | 6,451 |
| Michael Thomas Heffernan Director | Sep 15, 2026 | Option exercise | +21,052 | $3.33 | $70.10K | 27,403 |
| Michael Thomas Heffernan Director | Sep 15, 2026 | Sale(10b5-1 plan) | −100 | $15.88 | $1.59K | 6,351 |
| Michael Thomas Heffernan Director | Sep 15, 2026 | Sale(10b5-1 plan) | −18,321 | $15.09 | $276.46K | 6,451 |
| Michael Thomas Heffernan Director | Sep 15, 2026 | Option exercise | +18,421 | $3.04 | $56.00K | 24,772 |
| Christopher Galletta See Remarks | Dec 2, 2025 | Option exercise | +4,225 | $0.51 | $2.15K | 26,095 |
| Ali Behbahani 10% owner | Apr 17, 2025 | Option exercise | +1,851,852 | $1.37 | $2.54M | 12,273,280 |
| Anthony A. Florence Jr. 10% owner | Apr 17, 2025 | Option exercise | +1,851,852 | $1.37 | $2.54M | 12,273,280 |
| Paul Edward Walker 10% owner | Apr 17, 2025 | Option exercise | +1,851,852 | $1.37 | $2.54M | 12,273,280 |
| NEA Partners 16, L.P. 10% owner | Apr 17, 2025 | Option exercise | +1,851,852 | $1.37 | $2.54M | 12,273,280 |
| Mohamad Makhzoumi 10% owner | Apr 17, 2025 | Option exercise | +1,851,852 | $1.37 | $2.54M | 12,273,280 |
| Carmen Chang 10% owner | Apr 17, 2025 | Option exercise | +1,851,852 | $1.37 | $2.54M | 12,273,280 |
| Forest Baskett 10% owner | Apr 17, 2025 | Option exercise | +1,851,852 | $1.37 | $2.54M | 12,273,280 |
| Scott D. Sandell 10% owner | Apr 17, 2025 | Option exercise | +1,851,852 | $1.37 | $2.54M | 12,273,280 |
| Thomas Sciascia Chief Scientific Officer | Mar 25, 2025 | Option exercise | +2,631 | $1.43 | $3.76K | 224,004 |
| Thomas Sciascia Chief Scientific Officer | Mar 25, 2025 | Sale | −2,631 | $6.60 | $17.36K | 221,373 |
| Jennifer L. Good President & CEO, Director | Mar 21, 2025 | Sale | −5,263 | $6.58 | $34.63K | 213,313 |
| Jennifer L. Good President & CEO, Director | Mar 21, 2025 | Option exercise | +5,263 | $1.43 | $7.53K | 218,576 |
| Farrell Simon Chief Commercial Officer | Mar 10, 2025 | Sale(10b5-1 plan) | −76,963 | $6.73 | $517.96K | 81,250 |
| Farrell Simon Chief Commercial Officer | Mar 10, 2025 | Option exercise | +17,500 | $3.21 | $56.18K | 63,150 |
| Farrell Simon Chief Commercial Officer | Mar 10, 2025 | Option exercise | +63,813 | $3.91 | $249.51K | 126,963 |
| Farrell Simon Chief Commercial Officer | Mar 10, 2025 | Option exercise | +31,250 | $0.51 | $15.94K | 158,213 |
| Farrell Simon Chief Commercial Officer | Mar 10, 2025 | Sale(10b5-1 plan) | −4,350 | $7.15 | $31.10K | 76,900 |
| Lisa Delfini Chief Financial Officer | Jan 8, 2025 | Option exercise | +5,000 | $0.51 | $2.55K | 64,660 |
| Lisa Delfini Chief Financial Officer | Jan 7, 2025 | Option exercise | +1,000 | $0.51 | $510 | 59,660 |
| Christopher Galletta See Remarks | Dec 13, 2024 | Option exercise | +15,000 | $0.51 | $7.65K | 19,935 |
| Jennifer L. Good President & CEO, Director | Sep 9, 2024 | Sale | −1,840 | $3.04 | $5.59K | 213,313 |
| Jennifer L. Good President & CEO, Director | Sep 9, 2024 | Option exercise | +1,840 | $1.43 | $2.63K | 215,153 |
| Jennifer L. Good President & CEO, Director | Sep 6, 2024 | Sale | −4,219 | $3.03 | $12.78K | 213,313 |
| Jennifer L. Good President & CEO, Director | Sep 6, 2024 | Option exercise | +4,219 | $1.43 | $6.03K | 217,532 |
| Jennifer L. Good President & CEO, Director | Sep 5, 2024 | Option exercise | +40,277 | $1.43 | $57.60K | 253,590 |
| Jennifer L. Good President & CEO, Director | Sep 5, 2024 | Sale | −40,277 | $3.11 | $125.26K | 213,313 |
| Jennifer L. Good President & CEO, Director | Sep 4, 2024 | Option exercise | +10,981 | $1.43 | $15.70K | 224,294 |
| Jennifer L. Good President & CEO, Director | Sep 4, 2024 | Sale | −10,981 | $3.02 | $33.16K | 213,313 |
| Jennifer L. Good President & CEO, Director | Sep 3, 2024 | Option exercise | +3,863 | $1.43 | $5.52K | 217,176 |
| Jennifer L. Good President & CEO, Director | Sep 3, 2024 | Sale | −3,863 | $3.02 | $11.67K | 213,313 |
| David P. Meeker Director | Aug 27, 2024 | Sale | −4,555 | $2.93 | $13.35K | 352,489 |
| David P. Meeker Director | Aug 27, 2024 | Option exercise | +4,555 | $1.43 | $6.51K | 357,044 |
| Thomas Sciascia Chief Scientific Officer | Aug 19, 2024 | Sale | −16,496 | $2.96 | $48.83K | 220,315 |
| Thomas Sciascia Chief Scientific Officer | Aug 19, 2024 | Option exercise | +16,496 | $1.43 | $23.59K | 236,811 |
| Thomas Sciascia Chief Scientific Officer | Aug 16, 2024 | Sale | −18,660 | $2.76 | $51.50K | 220,315 |
| Thomas Sciascia Chief Scientific Officer | Aug 16, 2024 | Option exercise | +18,660 | $1.43 | $26.68K | 238,975 |
| Thomas Sciascia Chief Scientific Officer | Aug 15, 2024 | Sale | −12,745 | $2.79 | $35.56K | 220,315 |
| Thomas Sciascia Chief Scientific Officer | Aug 15, 2024 | Option exercise | +12,745 | $1.43 | $18.23K | 233,060 |
| Thomas Sciascia Chief Scientific Officer | Aug 14, 2024 | Option exercise | +100 | $1.43 | $143 | 220,415 |
| Thomas Sciascia Chief Scientific Officer | Aug 14, 2024 | Sale | −100 | $2.75 | $275 | 220,315 |
| Thomas Sciascia Chief Scientific Officer | May 29, 2024 | Option exercise | +59,354 | $2.19 | $129.99K | 267,801 |
| Thomas Sciascia Chief Scientific Officer | May 29, 2024 | Sale | −53,368 | $2.55 | $136.09K | 214,433 |
| Lisa Delfini Chief Financial Officer | May 22, 2024 | Sale | −4,350 | $2.64 | $11.48K | 53,279 |
| Lisa Delfini Chief Financial Officer | May 22, 2024 | Option exercise | +16,043 | $0.51 | $8.18K | 57,629 |
| Jennifer L. Good President & CEO, Director | May 20, 2024 | Sale | −25,037 | $2.86 | $71.61K | 213,313 |
| Jennifer L. Good President & CEO, Director | May 20, 2024 | Option exercise | +25,037 | $2.19 | $54.83K | 238,350 |
| Jennifer L. Good President & CEO, Director | May 10, 2024 | Option exercise | +4,578 | $2.19 | $10.03K | 217,891 |
| Jennifer L. Good President & CEO, Director | May 10, 2024 | Sale | −4,578 | $2.90 | $13.28K | 213,313 |
| Lisa Delfini Chief Financial Officer | Oct 11, 2023 | Option exercise | +2,292 | $0.51 | $1.17K | 36,686 |
| Lisa Delfini Chief Financial Officer | Oct 11, 2023 | Sale(10b5-1 plan) | −785 | $2.02 | $1.59K | 35,901 |
| Lisa Delfini Chief Financial Officer | Sep 11, 2023 | Sale(10b5-1 plan) | −711 | $2.20 | $1.56K | 34,394 |
| Lisa Delfini Chief Financial Officer | Sep 11, 2023 | Option exercise | +2,291 | $0.51 | $1.17K | 35,105 |
| Lisa Delfini Chief Financial Officer | Aug 11, 2023 | Sale(10b5-1 plan) | −682 | $2.36 | $1.61K | 32,814 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Trevi Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,351 shares on Sep 22, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael Thomas Heffernan Director | Sep 15, 2026 | 39,473 | $627.23K | Sep 15, 2026 | Exercise of Stock Options |
| Lisa Delfini Officer | Oct 7, 2025 | 108,650 | $1.03M | Oct 7, 2025 | Option Exercise |
| Lisa Delfini Officer | Oct 3, 2025 | 40,000 | $386.72K | Oct 3, 2025 | Option Exercise |
| Lisa Delfini Officer | Aug 27, 2025 | 312,855 | $2.53M | Aug 27, 2025 | Restricted Stock Units |
| Jennifer L. Good Officer | Mar 21, 2025 | 5,263 | $34.63K | Mar 21, 2025 | Options Exercise |
| Farrell Simon Officer | Mar 10, 2025 | 81,313 | $548.88K | Mar 10, 2025 | Options Exercise |
| Jennifer L. Good Officer | Sep 3, 2024 | 61,180 | $193.33K | Sep 3, 2024 | Option Exercise |
| David P. Meeker Officer | Aug 27, 2024 | 4,555 | $13.57K | Aug 27, 2024 | Option Exercise |
| Thomas Sciascia Officer | Aug 15, 2024 | 48,001 | $125.28K | Aug 15, 2024 | Options |
| Thomas Sciascia Officer | Aug 15, 2024 | 48,001 | $125.28K | Aug 15, 2024 | Options |
| Thomas Sciascia Officer | May 29, 2024 | 53,368 | $136.62K | May 29, 2024 | Options |
| Lisa Delfini Officer | Sep 11, 2023 | 1,600 | $3.46K | Sep 11, 2023 | Options Exercise |
| Lisa Delfini Officer | Jun 12, 2023 | 1,615 | $4.15K | Jun 12, 2023 | Options Exercise |
| Lisa Delfini Officer | Apr 11, 2023 | 1,900 | $3.50K | Apr 11, 2023 | Options Exercise |
See a number that looks wrong?